SEC Form 4 · accession 0001140361-18-038417
SIGA TECHNOLOGIES INC · SIGA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis E Hruby
Officer — VP & Chief Scientific Officer
Period of report
Sep 11, 2018
Accepted (ET)
Sep 13, 2018 · 7:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001010086
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1,F2 | Sep 11, 2018 | M | 18,174 | $3.53 | A | 226,314 | D | |
| Common Stock, par value $.0001 per shareF1,F2 | Sep 11, 2018 | F | 8,853 | $7.16 | D | 217,461 | D | |
| Common Stock, par value $.0001 per shareF4 | Sep 11, 2018 | M | 50,000 | $4.70 | A | 267,461 | D | |
| Common Stock, par value $.0001 per shareF4 | Sep 11, 2018 | F | 32,821 | $7.16 | D | 234,640 | D | |
| Common Stock, par value $.0001 per shareF6 | Sep 11, 2018 | M | 25,000 | $0.00 | A | 259,640 | D | |
| Common Stock, par value $.0001 per shareF6 | Sep 11, 2018 | F | 12,175 | $7.16 | D | 247,465 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-Settled Stock Appreciation RightsF3 | $3.53 | Sep 11, 2018 | M | 37,500 | D | — | Feb 2, 2022 | Common Stock, par value $.0001 per share | 37,500 | 0 | D |
| Stock Option (Right to buy)F5 | $4.70 | Sep 11, 2018 | M | 50,000 | D | — | Mar 5, 2019 | Common Stock, par value $.0001 per share | 50,000 | 0 | D |
| Restricted Stock UnitsF7 | — | Sep 11, 2018 | M | 25,000 | D | — | — | Common Stock, par value $.0001 per share | 25,000 | 0 | D |
Explanation of responses
- F1This Form 4 reports the exercise of 37,500 stock-settled appreciation rights ("SSARs") for shares of common stock of SIGA Technologies, Inc. (the "Issuer") granted on February 12, 2012 and the related surrender to the Issuer of 8,853 shares of common stock of the Issuer by the Reporting Person in order to satisfy certain tax withholding obligations of the Issuer associated with the exercise of SSARs and the consequent issuance of common stock of the Issuer. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction.
- F2Each SSAR consists of the right to receive an amount, in common stock, equal to the excess of the fair market value of a share of common stock of the Issuer (subject to a cap on the fair market value at $7.00 per share) on the date of exercise over the exercise price of such SSAR. The number of shares of common stock issued was determined by dividing the total of all exercised SSARs by the fair market value of a share of common stock of the Issuer on the date of exercise.
- F3The SSARs vested in equal yearly installments over a period of three (3) years, with the first 1/3 of such SSARs vesting on February 2, 2013, the second 1/3 of such SSARs vesting on February 2, 2014, and the remaining 1/3 of such SSARs vesting on February 2, 2015.
- F4This Form 4 reports the exercise of options for 50,000 shares of common stock of the Issuer granted on March 5, 2009 and the related surrender to the Issuer of 32,821 shares of common stock of the Issuer by the Reporting Person in order to effect the option exercise. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction.
- F5The options vested in equal yearly installments over a period of three (3) years, with the first 1/3 of such options vesting on March 5, 2010, the second 1/3 of such options vesting on March 5, 2011, and the remaining 1/3 of such options vesting on March 5, 2012.
- F6This Form 4 reports the vesting of 25,000 restricted stock units ("RSUs") granted on June 8, 2017 and the consequent issuance of common stock of the Issuer, and the related surrender to the Issuer of 12,175 shares of common stock of the Issuer by the Reporting Person in order to satisfy certain tax withholding obligations of the Issuer associated with the vesting of RSUs and the consequent issuance of common stock of the Issuer. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction. Each RSU converts into one share of common stock of the Issuer on a one for one basis.
- F7The RSUs vested upon the U.S. Food & Drug Administration's final approval of TPOXX for the treatment of orthopoxvirus infections.